Prospective Study
Copyright ©The Author(s) 2015.
World J Gastroenterol. Sep 28, 2015; 21(36): 10443-10452
Published online Sep 28, 2015. doi: 10.3748/wjg.v21.i36.10443
Figure 1
Figure 1 Flow chart of the treatment scheme. PFS: Progression free survival; ORR: Objective response rate; DCR: Disease control rate; HAIC: Hepatic arterial infusion chemotherapy; PVA: Polyvinyl alcohol particles; BCLC: Barcelona Clinic Liver Cancer staging.
Figure 2
Figure 2 Comparison of the median progression free survival in the chemoembolization + hepatic arterial infusion chemotherapy treatment group (group B) and chemoembolization alone treatment group (group A). HAIC: Hepatic arterial infusion chemotherapy.
Figure 3
Figure 3 Comparison of the median progression free survival in patients with different BCLC stages and patient state in the chemoembolization + hepatic arterial infusion chemotherapy treatment group (group B) and chemoembolization alone treatment group (group A). A: Hepatocellular carcinoma (HCC) patients with BCLC stage A/B disease; B: HCC patients with BCLC stage C disease; C: HCC patients without vessel invasion; D: HCC patients with vessel invasion. HAIC: Hepatic arterial infusion chemotherapy.